Fresenius Kabi closes Dabur Pharma acquisition
|
August 13, 2008
|
Fresenius Kabi has successfully closed the acquisition of Dabur Pharma Ltd. In April 2008, the company had announced the acquisition of 73.3% of the share capital for a price of INR 76.5 per share in cash. Fresenius Kabi has now acquired a further 17.6% shareholding for a price of INR 76.5 per share in cash through a public offer.
The acquisition significantly expands Fresenus Kabi’s drug portfolio and secures its supply of high quality APIs for cytostatics. Dabur Pharma, headquartered in New Delhi, is one of the leading suppliers of generic drugs and active pharmaceutical ingredients (API) to treat cancer. The company holds a substantial number of drug registrations in Asia, Europe and the US.
|
 |
Email this |
| About
Epitome Global
Services
|
|
Epitome Global Services is a trusted advisor to the global financial services industry with expertise in providing specialized, high value services to hedge funds, fund of hedge funds, fund administrators, and related businesses. Clients include leading names in the asset management, securities, and allied sectors.
|
|
|
|
|
To access our other publications and research products
click here |
|
|
|
|
| Words of Wisdom |
 |
Success is not final, failure is not fatal: it is the courage to continue that counts.
- Winston Churchill
|
|
|
|
